CARA - Cara Therapeutics, Inc.
24.25 +0.33 (1.38%)
After hours: 7:39PM EDT
| Previous Close | 22.20 |
| Open | 22.38 |
| Bid | 24.10 x 3000 |
| Ask | 24.37 x 800 |
| Day's Range | 22.30 - 24.01 |
| 52 Week Range | 11.11 - 24.01 |
| Volume | 1,598,894 |
| Avg. Volume | 972,243 |
| Market Cap | 939.829M |
| Beta | 3.53 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.85 |
| Earnings Date | Aug 3, 2017 - Aug 7, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 26.88 |
- ACCESSWIRE•2 days ago
CBD Stocks Set to Explode
HENDERSON, NV / ACCESSWIRE / September 19, 2018 / It's just a matter of time before medical marijuana will become legal in all 50 states. It's not surprising when you consider a recent poll shows 93% of ...
- ACCESSWIRE•2 days ago
Today's Research Reports on Trending Tickers: Madrigal Pharmaceuticals and Cara Therapeutics
NEW YORK, NY / ACCESSWIRE / September 19, 2018 / U.S. markets closed up Tuesday on the strength of upbeat corporate earnings and strong economic data. On Tuesday, China announced tariffs of between 5 to ...
- ACCESSWIRE•6 days ago
Major Stem Cell Breakthroughs Giving Investors Big Opportunity
HENDERSON, NV / ACCESSWIRE / September 14, 2018 / Last week, Sangamo Therapeutics became the first company to edit a patient's DNA inside the body, usually the process is done outside the body. This is ...
- Benzinga•7 days ago
Jefferies Projects $573M Peak Sales For Cara Therapeutics' Lead Candidate
Cara Therapeutics Inc (NASDAQ: CARA ), a biotech company developing non-opioid pain relief drugs, has earned a bullish review from Jefferies. The Analyst Analyst Matthew Andrews initiated coverage of Cara ...
- Motley Fool•8 days ago
Better Buy: Cara Therapeutics Inc. vs. Fresenius Medical Care AG & Co.
Which stock wins in a one-on-one matchup between these two partners?
- InvestorPlace•9 days ago
9 Marijuana Stocks to Play the Pot Craze
Marijuana stocks, fueled by what may well be the biggest legal and medical revolution in years, have already proven they’re blazing their own trail. In all cases, though, there’s explosive potential on the table — the legal marijuana industry’s story has just gotten that compelling, as more states seek to legalize it while regulators finally start to see its legitimate medical benefits. Of all the marijuana stocks worth a look right now, Canopy Growth (NYSE:CGC) has garnered the most attention of late.
- GlobeNewswire•15 days ago
Cara Therapeutics to Present at the 27th European Academy of Dermatology & Venereology Congress
STAMFORD, Conn., Sept. 05, 2018-- Cara Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively ...
- Motley Fool•16 days ago
Here's Why Cara Therapeutics Rose 12.5% in August
The company announced second-quarter 2018 earnings results and initiated a crucial late-stage clinical trial.
Market Realist•20 days agoHow Cara Therapeutics’ Top Line Is Trending
Cara’s product candidate Korsuva has demonstrated improvement in pruritus patients’ quality of life as well as efficacy in patients with moderate-to-severe pain without the side effects that are generally associated with opioid pain therapeutics currently on the market. The general and administrative expenses that Cara Therapeutics (CARA) has incurred increased from $2.67 million in the second quarter of 2017 to $3.68 million in the second quarter. Part 1 - How Is Insys Therapeutics Positioned in H2 2018?
Market Realist•20 days agoWhy Analysts Remain Bullish on Cara Therapeutics
Cara Therapeutics’ (CARA) other income increased from $331,000 in the second quarter of 2017 to $467,000 in the second quarter of 2018. The company received an income tax benefit of $152,000 in the second quarter of this year as compared to an income tax benefit of $2,000 in the second quarter of 2017.
Market Realist•20 days agoHow Is Insys Therapeutics Positioned in H2 2018?
The US government is taking steps to address the opioid epidemic and rapidly rising addiction levels in the country. On August 16, President Trump asked the Attorney General to start filing federal lawsuits against certain companies that supply opioids to hospitals. In this series, we’ll analyze the financial performance, products, analysts’ views, valuation metrics, and the stock performance of Insys Therapeutics (INSY), Cara Therapeutics (CARA), Collegium Pharmaceutical (COLL), and Pacira Pharmaceuticals (PCRX).
- GlobeNewswire•25 days ago
Analysis: Positioning to Benefit within C&J Energy Services, LivePerson, Kadmon, Cara Therapeutics, CorMedix, and Second Sight Medical Products — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Aug. 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of C&J ...
- Thomson Reuters StreetEvents•last month
Edited Transcript of CARA earnings conference call or presentation 7-Aug-18 8:30pm GMT
Q2 2018 Cara Therapeutics Inc Earnings Call
- Motley Fool•last month
3 Reasons Cara Therapeutics Is a Great Pick for Aggressive Investors
This biotech could deliver big returns for investors who aren't afraid of taking on considerable risk.
- Benzinga•last month
4 Cannabis Stocks In Uptrends This Week
It’s been an eventful few weeks in the cannabis market. Between Tilray Inc (NASDAQ: TLRY) IPOing to become the first cannabis-producing company on a major American exchange, Aurora Cannabis’ (OTC: ACBFF) $2.5 billion acquisition of Medreleaf Corp (OTC: MEDFF), and Acreage Holdings’ $119 million capital raise, headlines definitely have not been in short supply of late. Here are four cannabis stocks that short-term traders should have their eye on this week.To identify the trend we used VantagePoint Software, a market forecasting software that uses artificial intelligence to predict price action 1-3 days in advance with up to 86 percent accuracy.
- ACCESSWIRE•last month
Biotech and Cannabis Companies Set to Own The Future
HENDERSON, NV / ACCESSWIRE / August 8, 2018 / With investors piling into biotechnology, and cannabis stocks the future is upon us. Intelligent investors see the writing on the wall. Biotechnology, and ...
- Zacks•last month
Cara Therapeutics (CARA) Reports Q2 Loss, Tops Revenue Estimates
Cara (CARA) delivered earnings and revenue surprises of -4.00% and 359.84%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•last month
Cara: 2Q Earnings Snapshot
On a per-share basis, the Stamford, Connecticut-based company said it had a loss of 52 cents. The results fell short of Wall Street expectations. The average estimate of five analysts surveyed by Zacks ...
- GlobeNewswire•last month
Cara Therapeutics Reports Second Quarter 2018 Financial Results
STAMFORD, Conn., Aug. 07, 2018-- Cara Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively ...
- GlobeNewswire•last month
Cara Therapeutics Doses First Patient in Second Pivotal Phase 3 Efficacy Trial of KORSUVA™ (CR845/difelikefalin) Injection in Hemodialysis Patients with Chronic Kidney Disease-Associated Pruritus
Cara Therapeutics, Inc. (CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced the dosing of the first patient in its second pivotal Phase 3 efficacy trial (KALM™-2) of KORSUVA™ (CR845/difelikefalin) injection in hemodialysis patients suffering from moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). The global trial is expected to enroll hemodialysis patients in the U.S., Europe and some countries in the Pacific Rim region. The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to KORSUVA™ injection for this indication, for which there are currently no approved therapies in the U.S. or European Union (EU).
- GlobeNewswire•2 months ago
Cara Therapeutics Appoints Christopher A. Posner to Board of Directors
Cara Therapeutics, Inc. (CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced the appointment of Christopher A. Posner to its Board of Directors. “We are pleased to welcome Chris to our board,” said Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer of Cara Therapeutics.
- GlobeNewswire•2 months ago
Cara Therapeutics to Announce Second Quarter 2018 Financial Results on August 7, 2018
STAMFORD, Conn., July 31, 2018-- Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain ...
- ACCESSWIRE•2 months ago
Initiating Free Research Reports on Celgene and Three Other Biotech Equities
Stock Research Monitor: CARA, CLDX, and CORT LONDON, UK / ACCESSWIRE / July 27, 2018 / If you want a free Stock Review on CELG sign up now at www.wallstequities.com/registration . On Thursday, benchmark ...
- ACCESSWIRE•2 months ago
This Unknown Stock Could Trade From $3 to $10 As Wall Street Wakes Up
CNS disorders are seeing renewed interest from investors, and epilepsy has seen a particular resurgence in investor activity as numerous public companies have found success with new drugs and mechanisms. A little-known company called NeuroOne Medical (NMTC) is making strides with an all-new thin-film electrode technology, which comes from the labs of the Mayo Clinic. This prestigious institute is also a 10% stockholder in newly public NMTC.
- GlobeNewswire•2 months ago
Cara Therapeutics Announces Closing of Its Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
STAMFORD, Conn., July 23, 2018-- Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain ...
